DEPIXUS

In News

Depixus Announces Strategic Collaboration With Daiichi Sankyo to Use MAGNA™ Technology to Accelerate RNA-targeted Drug Discovery - Business Wire

Business Wire - Dec 12, 2023

Daiichi Sankyo and Depixus partner to accelerate RNA-targeted drug discovery - Pharmaceutical Technology

Pharmaceutical Technology - Dec 13, 2023

Depixus Appoints Steve Klose as Chief Commercial Officer to Drive the Commercialization of Its Groundbreaking MAGNA™ Technology - BioSpace

BioSpace - Jan 11, 2024

Daiichi Sankyo taps Depixus to speed RNA drug discovery - pharmaphorum

pharmaphorum - Dec 13, 2023

CoNAN projects: new generation of microchip-based tools for genetic analysis - European Innovation Council

European Innovation Council - Sep 05, 2023

The biotech bi-weekly: sequencing costs slashed again, biomolecular interactions measured by the thousands and a single-cell picking platform for lipid profiles validated - BioTechniques

BioTechniques - Nov 06, 2024

Depixus Launches Technology Access Program With First MAGNA One™ Instrument Placement - Business Wire

Business Wire - Jan 04, 2024

Depixus raises £26.8m in Series A round to power MAGNA dynamic genomics technology - Cambridge Independent

Cambridge Independent - Dec 24, 2021

Detection of genetic variation and base modifications at base-pair resolution on both DNA and RNA - Nature

Nature - Jan 29, 2021

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment